Cargando…

A Computational Cognitive Biomarker for Early-Stage Huntington’s Disease

Huntington’s disease (HD) is genetically determined but with variability in symptom onset, leading to uncertainty as to when pharmacological intervention should be initiated. Here we take a computational approach based on neurocognitive phenotyping, computational modeling, and classification, in an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiecki, Thomas V., Antoniades, Chrystalina A., Stevenson, Alexander, Kennard, Christopher, Borowsky, Beth, Owen, Gail, Leavitt, Blair, Roos, Raymund, Durr, Alexandra, Tabrizi, Sarah J., Frank, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752511/ https://www.ncbi.nlm.nih.gov/pubmed/26872129 http://dx.doi.org/10.1371/journal.pone.0148409

Ejemplares similares

Altered Intracortical T(1)-Weighted/T(2)-Weighted Ratio Signal in Huntington’s Disease
por: Rowley, Christopher D., et al.
Publicado: (2018)

Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study
por: Klöppel, Stefan, et al.
Publicado: (2015)

Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling
por: Minkova, Lora, et al.
Publicado: (2015)

Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington’s Disease
por: Johnson, Eileanoir B., et al.
Publicado: (2017)

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
por: Byrne, Lauren M, et al.
Publicado: (2017)

Natural biological variation of white matter microstructure is accentuated in Huntington's disease
por: Gregory, Sarah, et al.
Publicado: (2018)

Longitudinal expression changes are weak correlates of disease progression in Huntington’s disease
por: Mitchell, Christopher T, et al.
Publicado: (2020)

Statistical characteristics of finger-tapping data in Huntington’s disease
por: Antoniades, Chrystalina A., et al.
Publicado: (2012)

Neurofilament light protein in blood predicts regional atrophy in Huntington disease
por: Johnson, Eileanoir B., et al.
Publicado: (2018)

Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance
por: Keogh, Ruth, et al.
Publicado: (2016)

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease
por: Stout, Julie C, et al.
Publicado: (2012)

Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease
por: McColgan, Peter, et al.
Publicado: (2017)

Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease
por: Minkova, Lora, et al.
Publicado: (2017)

Progressive alterations in white matter microstructure across the timecourse of Huntington's disease
por: Estevez‐Fraga, Carlos, et al.
Publicado: (2023)

Testing a longitudinal compensation model in premanifest Huntington’s disease
por: Gregory, Sarah, et al.
Publicado: (2018)

Genetic topography and cortical cell loss in Huntington's disease link development and neurodegeneration
por: Estevez-Fraga, Carlos, et al.
Publicado: (2023)

Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study
por: Baake, Verena, et al.
Publicado: (2018)

Brain Regions Showing White Matter Loss in Huntington’s Disease Are Enriched for Synaptic and Metabolic Genes
por: McColgan, Peter, et al.
Publicado: (2018)

Disease Onset in Huntington's Disease: When Is the Conversion?
por: Oosterloo, Mayke, et al.
Publicado: (2021)

Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington’s disease
por: McColgan, Peter, et al.
Publicado: (2017)

A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes
por: Ciosi, Marc, et al.
Publicado: (2019)

Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington’s Disease
por: Mansoor, Nina M., et al.
Publicado: (2021)

Neuropsychiatry and White Matter Microstructure in Huntington’s Disease
por: Gregory, Sarah, et al.
Publicado: (2015)

A Comparison of Change Blindness in Real-World and On-Screen Viewing of Museum Artefacts
por: Attwood, Jonathan E., et al.
Publicado: (2018)

Learning and Recognition of a Non-conscious Sequence of Events in Human Primary Visual Cortex
por: Rosenthal, Clive R., et al.
Publicado: (2016)

Huntington's disease: a clinical review
por: Roos, Raymund AC
Publicado: (2010)

Longitudinal Structural MRI in Neurologically Healthy Adults
por: Gregory, Sarah, et al.
Publicado: (2020)

Eye Movements Discriminate Fatigue Due to Chronotypical Factors and Time Spent on Task – A Double Dissociation
por: Cazzoli, Dario, et al.
Publicado: (2014)

Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington’s disease
por: McColgan, Peter, et al.
Publicado: (2015)

White matter predicts functional connectivity in premanifest Huntington's disease
por: McColgan, Peter, et al.
Publicado: (2017)

Aspiration pneumonia and death in Huntington’s disease
por: Heemskerk, Anne-Wil, et al.
Publicado: (2012)

Potential biomarkers to follow the progression and treatment response of Huntington’s disease
por: Disatnik, Marie-Hélène, et al.
Publicado: (2016)

Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease
por: Rodrigues, Filipe Brogueira, et al.
Publicado: (2016)

Evaluation of multi-modal, multi-site neuroimaging measures in Huntington's disease: Baseline results from the PADDINGTON study()
por: Hobbs, Nicola Z., et al.
Publicado: (2012)

Cystathionine Levels in Patients With Huntington Disease
por: Aziz, N.A., et al.
Publicado: (2015)

Preface to the Special Issue on “Sleep and Circadian Disorder in Huntington’s Disease”
por: Leavitt, Blair R., et al.
Publicado: (2023)

Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease
por: Coppen, Emma M., et al.
Publicado: (2016)

EEG may serve as a biomarker in Huntington’s disease using machine learning automatic classification
por: Odish, Omar F. F., et al.
Publicado: (2018)

Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington’s Disease
por: Mazarei, Gelareh, et al.
Publicado: (2015)

Assessment of Cognitive Symptoms in Prodromal and Early Huntington Disease
por: Vaccarino, Anthony L, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3vu63hcs585qb572al6m6m4tp6